Statin Therapy-Evidence Beyond Lipid Lowering Contributing to Plaque Stability

Author(s): Ferruccio de Lorenzo, Michael Feher, Juliette Martin, Sophie Collot-Teixeira, Olena Dotsenko, John Louis McGregor

Journal Name: Current Medicinal Chemistry

Volume 13 , Issue 28 , 2006

Become EABM
Become Reviewer


Primarily statin drugs inhibit hepatic 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA)reductase, which is responsible for the reduction in circulating low-density lipoprotein (LDL) cholesterol.Several findings from recent research studies indicate that statins have multiple actions that favorablyinfluence key factors involved in the atherogenic process. These so-called pleiotropic properties affect variousaspects of cell function, inflammation, coagulation, and vasomotor activity. These effects are mediated eitherindirectly through LDL cholesterol reduction or via a direct effect on cellular functions. Such actions maycontribute to the early cardiovascular benefit observed in several outcome trials with statin drugs therapy.Although many of the pleiotropic properties of statins may be a class effect, some may be unique to certainagents and account for differences in their pharmacological activity. This review summarise the results of the major outcome trials of statins and non-statins therapy and thepossible mechanisms beyond lipid lowering contributing to plaque stability.

Keywords: Statins, pleiotropic effects, plaque stability, lipid lowering agents, coronary heart disease, thrombosis

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [3385 - 3393]
Pages: 9
DOI: 10.2174/092986706779010324
Price: $65

Article Metrics

PDF: 7